Search Results
Your search for ,ARE matches 21421 pages
Showing 5501 - 5550Impact of COVID-19 on Cancer Treatment and Early Detection: Data-Driven Insights
From a dramatic drop in caseloads to missed screenings and diagnoses as well as the emergence of telemedicine, COVID-19 turned the world of oncology upside down. During the National Comprehensive Cancer Network (NCCN) Virtual Oncology Policy Summit, “Defining the ‘New Normal’ 2021 and the State of...
FDA Pipeline: Designations for Therapies in Myelodysplastic Syndromes and Triple-Negative Breast Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted special designation status to treatments for myelodysplastic syndromes and advanced triple-negative breast cancer. Breakthrough Therapy Designation for Venetoclax in Combination With Azacitidine for Myelodysplastic Syndromes Venetoclax...
Nomograms for Predicting Outcomes With LuPSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
In a retrospective study reported in The Lancet Oncology, Gafita et al developed nomograms for predicting overall survival and prostate-specific antigen (PSA) progression-free survival outcomes in men receiving lutetium-177–PSMA (LuPSMA) treatment for metastatic castration-resistant prostate...
Implementation of a Program Providing Free Cancer Screenings, Same-Day Results
Evidence shows that early detection and treatment of cancer can significantly improve health outcomes. However, women in Mississippi—particularly in underserved populations—experience high rates of late-stage cancer diagnoses. A report published by Michelle Williams, PhD, and colleagues in the...
Expert Point of View: Carol Aghajanian, MD
“The phase III ENGOT/GCIG study1 proved to be negative, with no advantage seen with the extension of bevacizumab treatment,” said the abstract’s invited discussant, Carol Aghajanian, MD, Chief of the Medical Gynecologic Oncology Service at Memorial Sloan Kettering Cancer Center, New York. Dr....
Study Finds the COVID-19 Pandemic Created Significant Disruptions in Cancer Screenings at Federally Qualified Health Centers
A new study has found that the COVID-19 pandemic contributed to significant disruptions in breast, colorectal, and cervical cancer screenings at federally qualified health systems spanning 15 states across the United States. The postponed screenings have created backlogs that systems will need to...
Pembrolizumab/Lenvatinib Granted Regular Approval for Advanced Endometrial Carcinoma
On July 21, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with lenvatinib (Lenvima) for patients with advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR). These patients must have ...
Transvaginal Ultrasound Screening Misses More Cases of Endometrial Cancer in Black Women vs White Women
A screening tool used to evaluate the need for endometrial cancer biopsies in women frequently misses the signs of this cancer in Black women, according to a new study published by Kemi M. Doll, MD, and colleagues in JAMA Oncology. Dr. Doll, a gynecologic oncologist at the University of Washington...
Study Identifies MET Amplification as a Driver for Some Non–Small Cell Lung Cancers
A study published by D. Ross Camidge, MD, PhD, and colleagues in the Journal of Thoracic Oncology has helped to define MET amplification as a rare but potentially actionable driver for non–small cell lung cancer (NSCLC). Dr. Camidge said many of the major developments in the treatment of NSCLC have ...
Addition of AKT Inhibitor Ipatasertib to Abiraterone/Prednisolone in Metastatic Castration-Resistant Prostate Cancer With PTEN Loss
In the phase III IPATential150 trial reported in The Lancet, Christopher Sweeney, MD, and colleagues found that the addition of the AKT inhibitor ipatasertib to abiraterone and prednisolone produced a significant improvement in progression-free survival among patients with metastatic...
Breast-Conserving Surgery Plus Radiotherapy May Yield Better Survival Than Mastectomy With or Without Radiotherapy
In a Swedish cohort study reported in JAMA Surgery, de Boniface et al found that breast-conserving surgery plus radiation therapy for women with breast cancer was associated with better survival vs mastectomy with or without radiotherapy in analysis adjusting for comorbidities and socioeconomic...
Combination Ficlatuzumab and Cytarabine Show Clinical Activity in Relapsed/Refractory AML
Despite advances in the treatment of acute myeloid leukemia (AML), only 29.5% of patients with the cancer are alive 5 years after diagnosis. Even with aggressive therapy, just 30% of patients achieve a complete remission with a median survival of 7.5 months, making it imperative to develop novel...
Atezolizumab Plus Bevacizumab in Malignant Peritoneal Mesothelioma
A phase II study published by Kanwal Raghav, MBBS, MD, and colleagues in Cancer Discovery found that combination treatment with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab was well tolerated and resulted in a 40% objective response rate in patients with advanced malignant...
Study Estimates Costs Associated With Metastatic Breast Cancer Treatment May Increase Substantially in the Coming Decade
A study from the UNC Center for Health Promotion and Disease Prevention (HPDP) estimates that annual costs associated with metastatic breast cancer treatment among women in the United States will total $152.4 billion in 2030—nearly two and a half times the estimate for 2015 costs—due to an increase ...
MRI-Targeted vs Standard Biopsy for Prostate Cancer Screening in Men With Elevated PSA Levels
In a Swedish population-based noninferiority trial (STHLM3-MRI) reported in The New England Journal of Medicine, Eklund et al found magnetic resonance imaging (MRI)-targeted biopsy was noninferior to standard biopsy in detecting clinically significant cancers in men with elevated prostate-specific...
Consensus Statement From IASLC on Liquid Biopsy for Advanced NSCLC
As reported in the Journal of Thoracic Oncology by Christian Rolfo, MD, PhD, and colleagues, the International Association for the Study of Lung Cancer (IASLC) has issued a consensus statement on the use of liquid biopsy in advanced non–small cell lung cancer (NSCLC). Select recommendations are...
HER2-Specific CAR T-Cell Trial Addresses Pediatric Brain and Spinal Cord Tumors
Locoregional delivery of chimeric antigen receptor (CAR) T cells has resulted in objective responses in adults with glioblastoma, but the approach has not been evaluated in pediatric patients with brain and central nervous system tumors. The innovative, ongoing phase I BrainChild-01 trial is...
Real-World Survival Outcomes With Pertuzumab Plus T-DM1 for HER2-Positive Metastatic Breast Cancer
In a Canadian population-based retrospective cohort study reported in JAMA Oncology, Ethier et al identified real-world survival outcomes among women receiving pertuzumab and trastuzumab emtansine (T-DM1) for stage IV HER2-positive breast cancer, observing that outcomes appeared to be poorer than...
KIT Inhibitor Combination Shows Efficacy in Refractory GIST
In a phase Ib/IIa trial reported in JAMA Oncology, Wagner et al found that the combination of a type I KIT inhibitor, PLX9486, with the type II inhibitor sunitinib produced clinical benefit and improved progression-free survival rates in patients with refractory gastrointestinal stromal tumors...
Evandro de Azambuja, MD, PhD, Discusses the Short-HER Trial
Invited discussant of the Short-HER trial, Evandro de Azambuja, MD, PhD, Head of the Medical Support Team at the Institut Jules Bordet, Brussels, acknowledged the good outcomes in low- and intermediate-risk patients treated with either a short or long duration of trastuzumab but said 1 year of the...
Long-Term Analysis of Short-HER Trial of Adjuvant Trastuzumab
Long-term analysis of the Short-HER trial showed that 9 weeks of adjuvant trastuzumab conveyed benefits comparable to a 1-year course in patients with early HER2-positive breast cancer deemed to be at low or intermediate risk for recurrence. High-risk patients, however, derived considerably more...
Study Identifies Gut Microbes Associated With Combination Immunotherapy Response and Adverse Events
Researchers have found that specific intestinal microbiota signatures may correlate with high-grade adverse events and response to combined CTLA-4 and PD-1 blockade treatment. The study, published by Andrews et al in Nature Medicine, also identified a potential new strategy to treat toxicity—while...
Risk of Bleeding Complications During Central Venous Catheter Placement in Pediatric Patients With Cancer
In a retrospective cohort study reported in a research letter in JAMA Surgery, Stokes et al found that risk of minor bleeding events during central venous catheter placement in pediatric patients with cancer was significantly increased among those with platelet counts < 50 × 103/μL at the time...
Majority of Patients With Cancer Achieve Immune Response After COVID-19 Vaccination
In a U.S. and Swiss study, nearly all patients with cancer developed an immune response to COVID-19 mRNA vaccines 3 to 4 weeks after receiving their second dose. However, a small group of the patients exhibited no response, raising questions about how their protection against the virus will be...
Study Explores Ketogenic Diet and Intermittent Fasting in Patients With Brain Cancer
More research into the efficacy of a modified ketogenic diet may be beneficial for people with brain tumors, according to a new study published by Schreck et al in the journal Neurology. The diet, which is high in fat and low in carbohydrates, led to changes in the metabolism in the body and the...
SBRT Plus Pembrolizumab/Trametinib vs Gemcitabine in Locally Recurrent Resected Pancreatic Cancer
In a Chinese phase II trial reported in The Lancet Oncology, Zhu et al found that stereotactic body radiotherapy (SBRT) plus pembrolizumab and trametinib produced a modest—but statistically significant—overall survival benefit vs SBRT plus gemcitabine in patients with locally recurrent resected...
Expert Point of View: Jason J. Luke, MD
The invited discussant of LEAP-004, Jason J. Luke, MD, Associate Professor of Medicine and Director of the Cancer Immunotherapeutics Center, University of Pittsburgh Hillman Cancer Center, said the investigators of LEAP-0041 deserve credit for designing a study with a clearly defined...
Does the Presence of Neuronal Autoantibodies Contribute to Cognitive Impairment in Patients With Lung Cancer?
In a German prospective cross-sectional study reported in JAMA Oncology, Bartels et al found that a high proportion of patients with lung cancer had neuronal antibodies that may be associated with increased risk of cognitive impairment. As stated by the investigators, “Paraneoplastic neurological...
LEAP-004 Trial Update on Lenvatinib Plus Pembrolizumab After Disease Progression in Metastatic Melanoma
Longer follow-up of the LEAP-004 trial in metastatic melanoma upheld the benefit seen with the VEGF kinase inhibitor lenvatinib plus the PD-1 inhibitor pembrolizumab for patients experiencing disease progression on prior checkpoint blockade, investigators reported at the 2021 ASCO Annual Meeting.1 ...
Paul G. Richardson, MD, on Multiple Myeloma and COVID-19: An Update
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses challenges patients with multiple myeloma have faced as a result of the COVID-19 pandemic and the research he and his international colleagues are conducting to better understand these difficulties and improve patient care.
Effect of Obesity on Receipt of Chemotherapy in Patients With Colorectal Cancer
Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy relative to their body surface area than nonobese patients, according to results from a large meta-analysis reported by Slawinski et al at the ESMO World Congress on Gastrointestinal Cancer 2021 (Abstract...
Expert Point of View: Thomas Seufferlein, MD, PhD
The invited discussant of APACT,1 Thomas Seufferlein, MD, PhD, Professor of Medicine at the University of Ulm in Germany, said the updated overall survival data “suggest an improved outcome with nab-paclitaxel plus gemcitabine vs gemcitabine alone…. The combination improves long-term survival and...
APACT: 5-Year Overall Survival Data Suggest Improved Outcomes in Pancreatic Cancer With Nab-Paclitaxel Plus Gemcitabine
Five-year outcomes in the APACT trial uphold the overall survival benefit with nab-paclitaxel plus gemcitabine in the adjuvant treatment of patients with resected pancreatic cancer, according to Margaret A. Tempero, MD, Director of the University of California San Francisco Pancreas Center, who...
Expert Point of View: Mary-Ellen Taplin, MD
Invited discussant of the VISION trial, Mary-Ellen Taplin, MD, of Dana-Farber Cancer Institute, Boston, commented on the study, noting that she was a co-investigator of the trial. “Patients with metastatic castration-resistant prostate cancer have a number of treatment options. There are 10...
VISION Trial: Novel PSMA-Targeted Radiotherapy Improves Outcomes in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (LuPSMA)—an investigational radiolabeled small molecule—significantly improved radiographic progression-free survival and overall survival when added to the standard of care compared with the standard of care alone for men with metastatic castration-resistant prostate cancer...
Registry Provides Information on Pediatric Melanoma
Pediatric melanoma is a rare disease, with only around 400 cases diagnosed in the United States every year. To better understand this disease and how best to treat it, St. Jude Children’s Research Hospital scientists created a registry called Molecular Analysis of Childhood MELanocytic Tumors...
Study Investigates Influence of Race on Receipt of Care for Prostate Cancer
Black men most likely to benefit from advanced prostate cancer therapies are 11% less likely to receive them than non-Black men. This happens despite apparent equal opportunities in obtaining health-care services, a new study focused on American veterans has shown. Disparities Exposed Published by...
Evaluation of Two Doses of Imetelstat in Patients With Relapsed or Refractory Myelofibrosis After JAK Inhibitor Treatment
In a phase II trial reported in the Journal of Clinical Oncology, John Mascarenhas, MD, and colleagues found that treatment with the telomerase inhibitor imetelstat at a dose of 9.4 mg/kg produced clinical benefit in patients with relapsed or refractory myelofibrosis after Janus-associated kinase...
Genomic Characteristics of Pediatric Rhabdomyosarcoma Tumors
In an analysis from an international consortium reported in the Journal of Clinical Oncology, Shern et al identified genomic characteristics and associated outcomes in pediatric rhabdomyosarcoma. Among the findings were that MYOD1 and TP53 mutations were associated with poorer outcomes. As stated...
ASCO Releases New Recommendations on Systemic Therapy Dosing for Adults With Obesity and Cancer
ASCO has approved new recommendations for the appropriate dosing of systemic anticancer agents in adults with obesity and cancer.1 The guideline update was based on evidence collected from a systematic review of the literature published between November 1, 2010, and March 27, 2020, regarding dosing ...
Defining Cure in Multiple Myeloma
The past 2 decades have seen so many advances in the treatment of multiple myeloma; in addition, median patient survival has grown from just 3 years in the late 1990s to between 8 and 10 years today,1 with some patients exceeding that prognosis by many years. Although still considered a stubbornly...
Reflections on Evolution of Breast Cancer Care in India Over the Past 4 Decades
India has witnessed a major paradigm shift in the field of breast cancer and its management over the past 4 decades. The discipline of medical oncology has evolved exponentially over this period—a growth that few other scientific disciplines have experienced. Interventions at the individual,...
Conquer Cancer, the ASCO Foundation, Awards More Than $10 Million to Support Cancer Research
Conquer Cancer, the ASCO Foundation, is pleased to announce the recipients of its awards supporting researchers with projects spanning across many areas in cancer care, including immunotherapy, precision medicine, breast cancer, and palliative care. This year, Conquer Cancer is funding the largest...
Being Both a Cancer Provider and a Cancer Survivor Is a Rare Privilege
Perhaps my 35-year career as a surgical oncologist and researcher specializing in soft-tissue sarcomas should have prepared me to recognize the signs of chronic lymphocytic leukemia (CLL) when they first appeared a few days before Christmas in 2016, but it did not. In fact, my symptoms were so...
Expert Point of View: Edward B. Garon, MD, MS
Invited discussant of the BOOSTER trial,1 Edward B. Garon, MD, MS, Professor of Medicine and Director of the Thoracic Oncology Program, David Geffen School of Medicine at the University of California Los Angeles, said the study’s research question is appropriate, since osimertinib was established...
Study Finds Bevacizumab Offers No Boost to Second-Line Osimertinib in EGFR T790M–Mutated Lung Cancer
For the second-line treatment of advanced EGFR T790M–mutated non–small cell lung cancer (NSCLC), the performance of osimertinib alone was not found to be different from that of osimertinib plus bevacizumab in the phase II ETOP 10-16 BOOSTER trial, reported at a European Society for Medical...
Sarah Cannon Names Navneet Majhail, MD, MS, FASTCT, Deputy Physician-in-Chief of Blood Cancers
Sarah Cannon, the Cancer Institute of HCA Healthcare, announced that Navneet Majhail, MD, MS, FASTCT, has been named Deputy Physician-in-Chief of Blood Cancers for the Sarah Cannon Transplant and Cellular Therapy Network (formerly the Sarah Cannon Blood Cancer Network). In his role, Dr. Majhail...
New IASLC Leadership to Assume Roles at 2021 World Conference on Lung Cancer
Heather Wakelee, MD, will assume the role of President of the International Association for the Study of Lung Cancer (IASLC) at the upcoming IASLC 2021 World Conference on Lung Cancer Denver, Worldwide Virtual Event (WCLC 2021) on September 8 to 14, 2021. Dr. Wakelee has been President-Elect of...
Expert Point of View: Melinda Telli, MD
EA1131 study discussant, Melinda Telli, MD, Associate Professor of Medicine at Stanford University, Director of the Breast Cancer Program at the Stanford Cancer Institute, and Associate Director of the Stanford Women’s Cancer Center, commented: “At this point,1 capecitabine remains preferred as...
Julio Aguirre-Ghiso, PhD, to Lead New Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer Center
Albert Einstein Cancer Center (AECC), Albert Einstein College of Medicine, and Montefiore Health System have announced that cancer biologist Julio Aguirre-Ghiso, PhD, has been named founding Director of the Cancer Dormancy and Tumor Microenvironment Institute (CDTMI), Director of the Gruss-Lipper...
